Neurochemical correlates of synapse density in a Huntington's disease mouse model

被引:6
|
作者
Zarate, Nicole [1 ]
Gundry, Katherine [2 ]
Yu, Dahyun [1 ]
Casby, Jordan [3 ]
Eberly, Lynn E. [2 ,4 ]
Oz, Gulin [2 ]
Gomez-Pastor, Rocio [1 ]
机构
[1] Univ Minnesota, Med Sch, Dept Neurosci, 2101 6th St SE, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Ctr Magnet Resonance Res, Med Sch, Dept Radiol, Minneapolis, MN 55455 USA
[3] Univ Minnesota, Med Sch, Dept Pharmacol, Minneapolis, MN 55455 USA
[4] Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA
关键词
H-1-MRS; CK2 alpha prime; Huntington's disease; neurochemicals; synapse density; zQ175; MAGNETIC-RESONANCE-SPECTROSCOPY; IN-VIVO; PROJECTION NEURONS; GLUTAMATE UPTAKE; BRAIN; NEURODEGENERATION; RECEPTOR; EXPRESSION; BIOMARKERS; RECOVERY;
D O I
10.1111/jnc.15714
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Striatal medium spiny neurons are highly susceptible in Huntington's disease (HD), resulting in progressive synaptic perturbations that lead to neuronal dysfunction and death. Non-invasive imaging techniques, such as proton magnetic resonance spectroscopy (H-1-MRS), are used in HD mouse models and patients with HD to monitor neurochemical changes associated with neuronal health. However, the association between brain neurochemical alterations and synaptic dysregulation remains unknown, limiting our ability to monitor potential treatments that may affect synapse function. We conducted in vivo longitudinal H-1-MRS in the striatum followed by ex vivo analyses of excitatory synapse density of two synaptic circuits disrupted in HD, thalamo-striatal (T-S), and cortico-striatal (C-S) pathways, to assess the relationship between neurochemical alterations and changes in synapse density. We used the zQ175((Tg/0)) HD mouse model as well as zQ175 mice lacking one allele of CK2 alpha'(zQ175((Tg/0)):CK2 alpha'((+/-))), a kinase previously shown to regulate synapse function in HD. Longitudinal analyses of excitatory synapse density showed early and sustained reduction in T-S synapses in zQ175 mice, preceding C-S synapse depletion, which was rescued in zQ175:CK2 alpha'((+/-)). Changes in T-S and C-S synapses were accompanied by progressive alterations in numerous neurochemicals between WT and HD mice. Linear regression analyses showed C-S synapse number positively correlated with H-1-MRS-measured levels of GABA, while T-S synapse number positively correlated with levels of phosphoethanolamine and negatively correlated with total creatine levels. These associations suggest that these neurochemical concentrations measured by H-1-MRS may facilitate monitoring circuit-specific synaptic dysfunction in the zQ175 mouse model and in other HD pre-clinical studies.
引用
收藏
页码:226 / 241
页数:16
相关论文
共 50 条
  • [21] Imaging brain metabolism in a mouse model of Huntington's disease
    Farzana, Farheen
    McConville, Malcolm
    Hannan, Anthony
    Hatters, Danny
    Boughton, Berin
    PROTEIN SCIENCE, 2021, 30 : 27 - 27
  • [22] Altered dopaminergic function in a mouse model of Huntington's disease
    Dallérac, GM
    Milner, AJ
    Cummings, DM
    Vatsavayai, SC
    Hirst, MC
    Murphy, KPSJ
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2005, 76
  • [23] Dantrolene is neuroprotective in Huntington's disease transgenic mouse model
    Xi Chen
    Jun Wu
    Svetlana Lvovskaya
    Emily Herndon
    Charlene Supnet
    Ilya Bezprozvanny
    Molecular Neurodegeneration, 6
  • [24] ACMSD Provides Neuroprotection in a Mouse Model of Huntington's Disease
    Fink, K. D.
    Deng, P.
    Cameron, D.
    Brundin, L.
    Manfredsson, F. P.
    CELL TRANSPLANTATION, 2021, 30 : 5 - 6
  • [25] Therapeutic potential of erythropoietin in a mouse model of huntington's disease
    Rolfes, S.
    Boettcher, C.
    Priller, J.
    HUMAN GENE THERAPY, 2014, 25 (11) : A107 - A107
  • [26] Metformin therapy in a transgenic mouse model of Huntington's disease
    Ma, Thong C.
    Buescher, Jessica L.
    Oatis, Benjamin
    Funk, Jason A.
    Nash, Andrew J.
    Carrier, Raeann L.
    Hoyt, Kari R.
    NEUROSCIENCE LETTERS, 2007, 411 (02) : 98 - 103
  • [27] Striatal transplantation in a transgenic mouse model of Huntington's disease
    Dunnett, SB
    Carter, RJ
    Watts, C
    Torres, EM
    Mahal, A
    Mangiarini, L
    Bates, G
    Morton, AJ
    EXPERIMENTAL NEUROLOGY, 1998, 154 (01) : 31 - 40
  • [28] Minocycline is not beneficial in a phenotypic mouse model of Huntington's disease
    Diguet, E
    Rouland, R
    Tison, F
    ANNALS OF NEUROLOGY, 2003, 54 (06) : 841 - 842
  • [29] Striatal neurochemical changes in transgenic models of Huntington's disease
    Ariano, MA
    Aronin, N
    Difiglia, M
    Tagle, DA
    Sibley, DR
    Leavitt, BR
    Hayden, MR
    Levine, MS
    JOURNAL OF NEUROSCIENCE RESEARCH, 2002, 68 (06) : 716 - 729
  • [30] Effects of donepezil on amyloid-β and synapse density in the Tg2576 mouse model of Alzheimer's disease
    Dong, Hongxin
    Yuede, Carla M.
    Coughlan, Carolyn A.
    Murphy, Keely M.
    Csernansky, John G.
    BRAIN RESEARCH, 2009, 1303 : 169 - 178